Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Engraftment of strictly anaerobic oxygen-sensitive bacteria in irritable bowel syndrome patients following fecal microbiota transplantation does not improve symptoms

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Ulcerative Colitis-associated E. coli pathobionts potentiate colitis in susceptible hosts

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Personalized B cell response to the Lactobacillus rhamnosus GG probiotic in healthy human subjects: a randomized trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Irritable bowel syndrome, the microbiota and the gut-brain axis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Fecal microbiota transplantation in hepatic encephalopathy: a systematic review

    Publikation: Bidrag til tidsskriftReviewpeer review

  2. Effect of α-Hemolysin Producing E. coli in Two Different Mouse Strains in a DSS Model of Inflammatory Bowel Disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Ulcerative Colitis-associated E. coli pathobionts potentiate colitis in susceptible hosts

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Dysbiosis of the gut microbiome has been correlated with irritable bowel syndrome (IBS). Fecal microbiota transplantation (FMT) is being explored as a therapeutic option. Little is known of the mechanisms of engraftment of microbes following FMT and whether the engraftment of certain microbes correlate with clinical improvement in IBS. Microbiome data, from a previously reported placebo-controlled trial of treatment of IBS with FMT or placebo capsules, were used to investigate microbial engraftment 15 days, 1, 3 and 6 months after treatment through assessment of gains, losses and changes in abundance of amplicon sequence variants (ASVs) and microbial diversity (CHAO-1 richness) between the FMT group and the placebo group. These data were compared to changes in IBS Symptom Severity Scores (IBS-SSS). Twelve days of treatment with 25 daily multi-donor FMT capsules induced significant short- and long-term changes in the recipients' microbiomes for at least 6 months, with persistent engraftment of a variety of anaerobic bacteria from keystone genera, such as Faecalibacterium, Prevotella and Bacteroides and increased microbial diversity, particularly in patients with low initial diversity. FMT recipients lost ASVs after treatment, which was seen to a much lesser extent in the placebo group. No ASVs increased to a greater extent between FMT responders and non-responders following treatment. Major long-term changes, lasting for at least 6 months, in the gut microbiomes of IBS patients are seen following treatment with FMT capsules. None of these changes correlated with clinical improvement. The relationship between the microbiome and the etiology of IBS still remains unsolved.

OriginalsprogEngelsk
TidsskriftGut Microbes
Vol/bind13
Udgave nummer1
Sider (fra-til)1-16
Antal sider16
ISSN1949-0976
DOI
StatusUdgivet - 3 jun. 2021

Bibliografisk note

Funding Information:
This work was supported by the Danish Innovation Fund under Grant 7076-00129B, MICROHEALTH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript;Innovationsfonden [7076-00129B, MICROHEALTH].

ID: 65946271